Literature DB >> 23966559

A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer.

Elizabeth M Poole, I-Min Lee, Paul M Ridker, Julie E Buring, Susan E Hankinson, Shelley S Tworoger.   

Abstract

Chronic inflammation may play a role in ovarian carcinogenesis. We examined associations between 3 plasma biomarkers of inflammation-C-reactive protein (CRP), interleukin 6, and tumor necrosis factor α receptor 2-and risk of invasive epithelial ovarian cancer in prospectively collected samples from the Nurses' Health Study (NHS; 1989-2010), Nurses' Health Study II (NHS II; 1996-2009), and the Women's Health Study (WHS; 1992-2011) and performed a meta-analysis including data from previous publications. Associations with ovarian cancer risk were calculated using logistic regression (NHS/NHS II; n = 217 cases) or Cox proportional hazards regression (WHS; n = 159 cases). Study-specific results were combined using random-effects meta-analysis. In the NHS/NHS II and WHS, we observed a 53% increased risk of invasive ovarian cancer when comparing women in the fourth quartile of CRP with women in the first quartile (95% confidence interval (CI): 1.05, 2.23). A CRP level of >10 mg/L versus a level of ≤1 mg/L was associated with a 2.16-fold increased risk (95% CI: 1.23, 3.78). In a meta-analysis of published studies, women in the third tertile of CRP had a 35% increased risk (95% CI: 1.10, 1.67) compared with women in the first tertile. There were no significant associations between interleukin 6 or tumor necrosis factor α receptor 2 and risk in the NHS/NHS II. Our results support the hypothesis that higher levels of circulating CRP are associated with increased risk of ovarian cancer, indicating that the role of inflammation in ovarian cancer requires further elucidation.

Entities:  

Keywords:  C-reactive protein; interleukin 6; ovarian cancer; tumor necrosis factor α receptor 2

Mesh:

Substances:

Year:  2013        PMID: 23966559      PMCID: PMC3792725          DOI: 10.1093/aje/kwt098

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  52 in total

1.  Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States).

Authors:  Patricia G Moorman; Joellen M Schildkraut; Brian Calingaert; Susan Halabi; Marilyn F Vine; Andrew Berchuck
Journal:  Cancer Causes Control       Date:  2002-11       Impact factor: 2.506

2.  Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection.

Authors:  Jennifer K Pai; Gary C Curhan; Carolyn C Cannuscio; Nader Rifai; Paul M Ridker; Eric B Rimm
Journal:  Clin Chem       Date:  2002-10       Impact factor: 8.327

3.  Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer.

Authors:  Kathryn L Terry; Linda Titus-Ernstoff; John R McKolanis; William R Welch; Olivera J Finn; Daniel W Cramer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-01       Impact factor: 4.254

4.  The effect of including C-reactive protein in cardiovascular risk prediction models for women.

Authors:  Nancy R Cook; Julie E Buring; Paul M Ridker
Journal:  Ann Intern Med       Date:  2006-07-04       Impact factor: 25.391

5.  Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2.

Authors:  W L Roberts; L Moulton; T C Law; G Farrow; M Cooper-Anderson; J Savory; N Rifai
Journal:  Clin Chem       Date:  2001-03       Impact factor: 8.327

6.  Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies.

Authors:  Claudio Pelucchi; Carlotta Galeone; Renato Talamini; Cristina Bosetti; Maurizio Montella; Eva Negri; Silvia Franceschi; Carlo La Vecchia
Journal:  Am J Obstet Gynecol       Date:  2007-01       Impact factor: 8.661

7.  C-reactive protein concentrations and subsequent ovarian cancer risk.

Authors:  Meghan A McSorley; Anthony J Alberg; Diane S Allen; Naomi E Allen; Louise A Brinton; Joanne F Dorgan; Michael Pollak; Yuzhen Tao; Kathy J Helzlsouer
Journal:  Obstet Gynecol       Date:  2007-04       Impact factor: 7.661

Review 8.  Chronic inflammation and cancer.

Authors:  Emily Shacter; Sigmund A Weitzman
Journal:  Oncology (Williston Park)       Date:  2002-02       Impact factor: 2.990

9.  Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.

Authors:  V Beral; R Doll; C Hermon; R Peto; G Reeves
Journal:  Lancet       Date:  2008-01-26       Impact factor: 79.321

10.  Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer.

Authors:  Lukas A Hefler; Nicole Concin; Gerda Hofstetter; Christian Marth; Alexander Mustea; Jalid Sehouli; Robert Zeillinger; Heinz Leipold; Harald Lass; Christoph Grimm; Clemens B Tempfer; Alexander Reinthaller
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

View more
  47 in total

1.  Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.

Authors:  Britton Trabert; Ligia Pinto; Patricia Hartge; Troy Kemp; Amanda Black; Mark E Sherman; Louise A Brinton; Ruth M Pfeiffer; Meredith S Shiels; Anil K Chaturvedi; Allan Hildesheim; Nicolas Wentzensen
Journal:  Gynecol Oncol       Date:  2014-08-23       Impact factor: 5.482

2.  Periodontal bone loss and risk of epithelial ovarian cancer.

Authors:  Ana Babic; Elizabeth M Poole; Kathryn L Terry; Daniel W Cramer; Ricardo P Teles; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2015-04-03       Impact factor: 2.506

3.  Plasma C-reactive protein and risk of breast cancer in two prospective studies and a meta-analysis.

Authors:  Jun Wang; I-Min Lee; Shelley S Tworoger; Julie E Buring; Paul M Ridker; Bernard Rosner; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-05-20       Impact factor: 4.254

4.  High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.

Authors:  Lauren C Peres; Adrianne R Mallen; Mary K Townsend; Elizabeth M Poole; Britton Trabert; Naomi E Allen; Alan A Arslan; Laure Dossus; Renée T Fortner; Inger T Gram; Patricia Hartge; Annika Idahl; Rudolf Kaaks; Marina Kvaskoff; Anthony M Magliocco; Melissa A Merritt; J Ramón Quirós; Anne Tjonneland; Antonia Trichopoulou; Rosario Tumino; Carla H van Gils; Kala Visvanathan; Nicolas Wentzensen; Anne Zeleniuch-Jacquotte; Shelley S Tworoger
Journal:  Cancer Res       Date:  2019-08-28       Impact factor: 12.701

5.  Prediagnostic Proinflammatory Dietary Potential Is Associated with All-Cause Mortality among African-American Women with High-Grade Serous Ovarian Carcinoma.

Authors:  Lauren C Peres; James R Hebert; Bo Qin; Kristin A Guertin; Elisa V Bandera; Nitin Shivappa; Tareq F Camacho; Deanna Chyn; Anthony J Alberg; Jill S Barnholtz-Sloan; Melissa L Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Edward S Peters; Ann G Schwartz; Paul D Terry; Joellen M Schildkraut
Journal:  J Nutr       Date:  2019-09-01       Impact factor: 4.798

6.  Invited Commentary: Relationship Between Ovulation and Markers of Systemic Inflammation Versus Markers of Localized Inflammation.

Authors:  Joellen M Schildkraut
Journal:  Am J Epidemiol       Date:  2020-07-01       Impact factor: 4.897

7.  Estimated Number of Lifetime Ovulatory Years and Its Determinants in Relation to Levels of Circulating Inflammatory Biomarkers.

Authors:  Tianyi Huang; Amy L Shafrir; A Heather Eliassen; Kathryn M Rexrode; Shelley S Tworoger
Journal:  Am J Epidemiol       Date:  2020-07-01       Impact factor: 4.897

8.  Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies.

Authors:  Mollie E Barnard; Elizabeth M Poole; Gary C Curhan; A Heather Eliassen; Bernard A Rosner; Kathryn L Terry; Shelley S Tworoger
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

Review 9.  Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.

Authors:  Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

Review 10.  Nurses' Health Study Contributions on the Epidemiology of Less Common Cancers: Endometrial, Ovarian, Pancreatic, and Hematologic.

Authors:  Brenda M Birmann; Mollie E Barnard; Kimberly A Bertrand; Ying Bao; Marta Crous-Bou; Brian M Wolpin; Immaculata De Vivo; Shelley S Tworoger
Journal:  Am J Public Health       Date:  2016-07-26       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.